• GT 1a with cirrhosis has lower response if NS5A polymorphism is present
  • GT = Genotype; CP = Child-Pugh
HCV cure rates for daclatasvir + sofosbuvir ± ribavirin
GT No cirrhosis or CP A CP B/C
1 > 90% B > 90%
C ∼ 50%
3 > 90% ∼ 60%

  • SVR 12 - sustained virological response at 12 weeks (cure)
  • Genotype 1a NS5A polymorphisms at M28, Q30, L31, Y93;
    Genotype 3 NS5A polymorphisms at Y93H
  • Results are pooled from ALLY-1 and ALLY-2 trials
  • Genotype 1a patients received sofosbuvir + daclatasvir ± ribavirin
  • References [1]
Patient population SVR 12
with polymorphism
SVR 12
without polymorphism
Genotype 1a
(overall)
76% (13/17) 95% (142/149)
Genotype 1a
without cirrhosis
100% (11/11) 99% (100/101)
Genotype 1a
with cirrhosis
33% (2/6) 88% (42/48)
Genotype 3
(overall)
54% (7/13) 92% (149/162)
Genotype 3
without cirrhosis
67% (6/9) 98% (125/128)
Genotype 3
with cirrhosis
25% (1/4) 71% (24/34)


Reference [1]
Side effect Incidence
(N=152)
Headache 14%
Fatigue 14%
Nausea 8%
Diarrhea 5%